Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report.
T lymphocytes
acute lymhoblastic leukemia
bone marrow microenviroment
donor lymphocyte infusion (DLI)
ponatinib
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
01
2020
accepted:
15
05
2020
entrez:
7
7
2020
pubmed:
7
7
2020
medline:
7
7
2020
Statut:
epublish
Résumé
Currently, the prognosis of Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients relapsing after an allogenic hematopoietic stem cell transplantation (allo-SCT) remains poor, with few therapeutic options available. Here we present the case of a 32 years old patient with dasatinib-resistant post-transplant molecular relapse of ALL, who received, as second-line therapy, the combination of ponatinib and donor lymphocyte infusion (DLI). The therapy was safe and the patient achieved a sustained minimal residual disease negative disease, still ongoing after 22 months, which was accompanied by several changes in the immune populations distribution within the bone marrow (i.e., the increase in the CD8/CD4 lymphocytes ratio). Our report provides evidence of the efficacy of the third generation TKI inhibitor ponatinib in combination with DLI as second line therapy for Ph+ ALL relapsing after an allo-SCT.
Identifiants
pubmed: 32626658
doi: 10.3389/fonc.2020.00967
pmc: PMC7314974
doi:
Types de publication
Case Reports
Langues
eng
Pagination
967Informations de copyright
Copyright © 2020 Botta, Caruso, Bossio, Storino, Console, Martino, Mendicino, Lucia, Morelli, Correale, Morabito, Gentile and Vigna.
Références
Leuk Res. 2009 Jan;33(1):174-7
pubmed: 18471874
Leuk Res. 2019 Apr;79:27-33
pubmed: 30831480
Future Sci OA. 2019 Apr 12;5(5):FSO380
pubmed: 31245042
Bone Marrow Transplant. 2008 Mar;41(5):483-93
pubmed: 18026156
Pharmacoeconomics. 2018 Jul;36(7):759-768
pubmed: 29502175
Cancer. 2016 Jul 15;122(14):2178-85
pubmed: 27143254
Leukemia. 2012 Jun;26(6):1211-7
pubmed: 22290066
Blood. 2012 Jan 5;119(1):273-84
pubmed: 22072555
Am J Hematol. 2017 Mar;92(3):279-285
pubmed: 28052371
Br J Haematol. 2003 Jan;120(1):145-53
pubmed: 12492591
Int J Hematol. 2008 Oct;88(3):331-335
pubmed: 18696183
Blood. 2007 Feb 1;109(3):944-50
pubmed: 17032921
Chemotherapy. 2017;62(6):353-356
pubmed: 28810255
Leuk Lymphoma. 2011 Jul;52(7):1376-9
pubmed: 21438838
Blood. 2017 Jan 5;129(1):3-4
pubmed: 28057668
Cell Death Dis. 2016 Jul 21;7:e2299
pubmed: 27441651
Hematology Am Soc Hematol Educ Program. 2008;:381-9
pubmed: 19074114
Haematologica. 2015 Mar;100(3):295-9
pubmed: 25740105
Front Oncol. 2019 Sep 24;9:939
pubmed: 31612105
Front Immunol. 2017 Apr 24;8:469
pubmed: 28484463